This study sought to understand the effect of MiR-144-3p in papillary thyroid carcinoma (PTC) as well as the associated mechanisms. Materials and methods Real-time PCR, immunohistochemical and Western blot assays were performed to examine the expression of target miRNA and/or genes. genes, cyclin D1, cyclin-dependent kinase 2 and CDC25A were modulated by miR-144-3p. SP2509 (HCI-2509) Meanwhile, the presence or absence of miR-144-3p both affected epithelial-mesenchymal transition of PTC by regulating the expression of E-cadherin, N-cadherin and vimentin. Moreover, PAX8 may be a potential direct target of miR-144-3p. Mechanically, the activation of extracellular signalCregulated kinases 1/2, Akt and c-Jun N-terminal kinases may be associated with Rabbit polyclonal to ZBED5 the tumor-promoting effect of miR-144-3p. In addition, the blockage of miR-144-3p forced the anti-tumor effect delivered by X-ray exposure or paclitaxel. Conclusion MiR-144-3p promoted the growth of tumor and the metastasis of PTC by targeting PAX 8. The study provided promising prognosis markers and valuable treatment strategy for PTC. normal tissue, cancer tissue Open in a SP2509 (HCI-2509) separate window Fig.?2 a Quantitative analysis was performed for expression level of miR-144-3p in cancer and adjacent normal tissues. b Paired T test was carried out for miR-144-3p expression between cancer and normal tissues. ***P? ?0.001. c Cell viability of PTC cells. *P? ?0.05 vs. control MiR-144-3p inhibitors reduced proliferation and induced cell cycle arrest of PTC cells Un-controlled growth is a typical character of tumor cells. The cells were treated and grouped as follows: Control, untreated PTC cells; mimics, PTC cells transfected with miR-144-3p mimics; inhibitor: PTC cells transfected with miR-144-3p inhibitors; NC, PTC cells transfected with miRNA unfavorable control. The CCK-8 assay result indicated that this increased expression of miR-144-3p augmented the cell viability of PTC cells, while its SP2509 (HCI-2509) suppressed expression reduced the cell viability (Fig.?2c). Researchers pointed out that the cell proliferation was largely dependent on the normal progression of cell cycle , therefore, the cell cycle progression was tested (Fig.?3a, b). The results from our tested showed that in miR-144-3p inhibitor group the cell populations at G1 phase increased significantly but decreased largely at G2/M, if being compared to control group. The proportion of cell in S phase was less in miR-144-3p inhibitor group than that those in control group. However, the effect of miR-144-3p mimics was the opposite, although no significant differences was observed. The expression of cell-cycle-related proteins, including CDK2, CDC25A and cycline D1, were also determined. Noticeably, the mRNA and SP2509 (HCI-2509) protein expression of these factors was increased by miR-144-3p mimics but decreased by inhibitor (Fig.?3c, d). Open in a separate window Fig.?3 a, b Flow cytometry analysis was applied for cell cycle distribution. c, d Western blot was used for expression of CDK2, CDC25A and cyclin D1. e Quantitative analysis was used for expression of CDK2, CDC25A and cyclin D1. *P? ?0.05 and **P? ?0.01 vs. control MiR-144-3p modulated the expression of metastasis associated proteins in PTC cells Another feature of cancer cells is the ability of metastasis. Epithelial-mesenchymal transition (EMT) is a primary mechanism responsible for SP2509 (HCI-2509) metastasis, which is usually accompanied with the acquirement of mesenchymal phenotypes and the loss of cell polarity. E-cadherin, N-cadherin and vimentin are the proteins participate in EMT . Thus, we applied RT-PCR and Western blot assays to analyse the expressions of EMT-associated proteins (Fig.?4aCc). Data showed that the expression of E-cadherin was reduced by miR-144-3p, while the expressions of N-cadherin and vimentin were increased by miR-144-3p. By contrast, the expressions of E-cadherin, N-cadherin and vimentin in miR-144-3p inhibitor group were reversed. Open in a separate window Fig.?4 a Quantitative analysis was performed for expression of E-cadherin, N-cadherin, and vimentin. b, c.